Variable Effect of Kinase Inhibitors on Breast Cancer Cell Lines

Breast tumors belonging to the triple negative subgroup (TN) (no estrogen, no progesterone and no ERBB2 receptors expressed) are the most aggressive and have the worst prognosis due to lack of specific therapies. The tyrosine kinases of the ABL family are responible for chronic myeloid leukemia (CML) and may be implicated in TN breast cancer too. Here we tested the ABL kinase inhibitors used for CML in TN cell lines. We unexpectedly found opposite effects of these inhibitors dependending on the TN cell line tested. Thus, ABL inhibitors may be beneficial only for a subset of TN patients and very dangerous for others.


New publication: ABL Tyrosine Kinase Inhibition Variable Effects on the Invasive Properties of Different Triple Negative Breast Cancer Cell Lines.
Authors: Chevalier C, Cannet A, Descamps S, Sirvent A, Simon V, Roche S, Benistant C
Journal: PLoS One, 2015 Mar 24;10(3)
Link to this article

Two CBS students receive prizes for youg researchers

Congratulations to Patrice Rassam (PhD student 2008-2012 in the team of P.E. Milhiet) who has just been selected to receive the "Prix du Jeune Chercheur" of the Société Francaise de Biophysique. He will recieve his prize and give an oral presentation during the EBSA Congress in Dresden, Germany, July 2015.

Congratulations to Linnea Olofsson (PhD student 2010-2014 in the team of E. Margeat) who will recieve the prize « Les Grandes Avancées en Biologie-Santé » from the Pôle BioSanté Rabelais on June 3rd 2015 (Genopolys).